Business Wire

The FINEOS Platform Winter Release Delivers Group, Voluntary and Absence Management Enhancements Essential to Insurers, Employers, and Employees

Share

The FINEOS Corporation (ASX:FCL), the leading core platform for life, accident and health insurance globally, released a set of product updates within the cloud-native FINEOS Platform that provide expanded capabilities across Group, Voluntary, and Absence Management products. The updates fulfil needs throughout the full customer spectrum across insurers, employers, and employees to support sales and service effectiveness, new product speed to market, and an enriched customer experience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005534/en/

To gain deeper insights into the FINEOS Platform Winter Release, join the live product management panel discussion: The FINEOS Platform: Purpose-Built for Innovation and Growth on April 14, 2022 at 11:30 am ET.

"This release marks another significant step forward in how the FINEOS Platform serves all parts of the Group, Voluntary, and Absence value chain. We are solving more problems for our customers and doing so in uniquely seamless ways,” said Eoin Kirwan, Chief Product Officer, FINEOS.

The FINEOS Platform Group, Voluntary, and Absence Management Enhancements Include:

Sales and Underwriting Effectiveness

  • Integrated Experience Rating: NextGen functionality for the underwriting and actuarial teams to drive profitability across their book of business. Via an embedded user experience, an underwriter can leverage prior claims experience to provide the best appropriate rate for the customer while providing leading risk management principles for the insurer. The experience rate is blended with the manual rate based upon insurer rules and preferences.
  • Enhanced Group Underwriting provides one view of the employer at time of quote: Integrated pricing flexibility and enhanced underwriting processes provides real time adjustment to changing market needs. Whole case underwriting enables optimized product bundles based on the employer’s total need and drives greater enrollment participation.
  • LIMRA LDEx API Enhancements: Enhanced LIMRA LDEx APIs include absence management connectivity and data management.

New Product Speed to Market

  • Voluntary Benefits Product Enhancements for Policy, Billing, and Claims: Enhanced claims integration and automation capabilities for accident, critical illness, and hospital indemnity enables insurers to leverage integrated eligibility and enrollment data for member elections to drive voluntary product claim acceleration and auto adjudication.
  • Additional Member Management and Bill Processing: This release provides extended support for the variety of administrative models across group insurance and worksite for member management.
  • Billing Enhancements: Enhancedlist bill processing supports the increased consumer centric product and services required by the market with additional billing support for insured Paid Family and Medical Leave (PFML) policies.

Customer Experience

  • Robust Employer Dashboard and Reporting Portal and APIs: Real-time data dashboards enable employers to view workforce leave information and review data in graphical views, filter the data by leave reason, groups, and dates. Reports can be exported in Excel or PDF formats to gain insight into individual case details.
  • Intermittent Leave Process Improvement: This releasereduces friction associated with intermittent leave, including surfacing the right level of information and automation, low-touch, and no-touch options, such as over-frequency tolerance rule.
  • Paid Leave Integration: Enriched integration and automation between paid leave, unpaid leave, disability, and voluntary benefits that pertain to an employee’s single leave reason, reduces duplicate work and errors, and providing a single source of truth across the value chain for all elements of an employee’s leave claim.

“As the only purpose-built, cloud-native core insurance solution for the life, accident and health market, the FINEOS Platform remains ahead of the curve in meeting the technical and operational needs of insurers,” said Michael Kelly, CEO, FINEOS. “Deployable as an end-to-end core solution, or as components to enable incremental transformation efforts, the FINEOS Platform has something for the entire Employee Benefits value chain including better support for the sales/service process, the customer experience and the ability to deal with a broad range of products and services such as absence management,” added Kelly.

About FINEOS Corporation
FINEOS is a leading provider of core systems for life, accident and health insurers globally with 7 of the 10 largest employee benefits insurers in the US as well as 6 of the largest life insurers in Australia. With employees and offices throughout the world, FINEOS continues to scale rapidly, working with innovative, progressive insurers in North America, Europe, and Asia Pacific.

The FINEOS Platform is the only purpose-built, end-to-end SaaS insurance solution for the life, accident and health market. The FINEOS AdminSuite delivers industry leading capabilities across core administration including absence management, billing, claims, payments, policy administration, provider management and new business and underwriting; all of which are configurable to operate independently or as one suite. The machine learning enabled FINEOS Engage solution enables robust people first digital engagement pathways and the FINEOS Insight solution provides predictive analytics and reporting across the business.

For more information, visit www.FINEOS.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Victoria Jamison
Sr Marketing Manager
FINEOS Corporation
+ 353 1 639 9700
victoria.jamison@fineos.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye